Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Drug Metabolism And Disposition

• Publication date

  2017-10-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1124/dmd.116.074567PMID 28646080
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro to in vivo extrapolation of the complex drug‐drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation

  2017cited by this paper
• Mechanisms of xenobiotic receptor activation: Direct vs. indirect.

  2016cited by this paper
• Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells

  2016cited by this paper
• CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver

  2016cited by this paper
• Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation

  2016cited by this paper
• Evaluation of CYP2B6 Induction and Prediction of Clinical Drug–Drug Interactions: Considerations from the IQ Consortium Induction Working Group—An Industry Perspective

  2016cited by this paper
• CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids.

  2016cited by this paper
• Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease

  2016cited by this paper
• Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes

  2016cited by this paper
• MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.

  2015cited by this paper
• Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac

  2015cited by this paper
• High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes

  2015cited by this paper
• Pharmacokinetic Drug Interaction Studies with Enzalutamide

  2015cited by this paper
• Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study

  2015cited by this paper
• Study of the in vitro cytotoxicity testing of medical devices.

  2015cited by this paper
• Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture

  2015cited by this paper
• High Content Imaging (HCI) on Miniaturized Three-Dimensional (3D) Cell Cultures

  2015cited by this paper
• Metformin Represses Drug-Induced Expression of CYP2B6 by Modulating the Constitutive Androstane Receptor Signaling

  2014cited by this paper
• Evaluation of 23 Lots of Commercially Available Cryopreserved Hepatocytes for Induction Assays of Human Cytochromes P450

  2014cited by this paper
• Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction Data

  2014cited by this paper
• Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk

  2014cited by this paper
• Altered CYP2C9 Activity Following Modulation of CYP3A4 Levels in Human Hepatocytes: an Example of Protein-Protein Interactions

  2014cited by this paper
• Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

  2013cited by this paper
• PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers

  2013cited by this paper
• In vitro models for liver toxicity testing.

  2013cited by this paper
• Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6

  2013cited by this paper
• Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper

  2013cited by this paper
• A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

  2013cited by this paper
• Organotypic liver culture models: Meeting current challenges in toxicity testing

  2012cited by this paper
• Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers

  2012cited by this paper
• Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins

  2012cited by this paper
• An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

  2012cited by this paper
• Estradiol induces cytochrome P450 2B6 expression at high concentrations: implication in estrogen-mediated gene regulation in pregnancy.

  2012cited by this paper
• Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation

  2012cited by this paper
• Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.

  2012cited by this paper
• Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

  2012cited by this paper
• Improved cryopreservation of human hepatocytes using a new xeno free cryoprotectant solution.

  2012cited by this paper
• Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene.

  2011cited by this paper
• Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir

  2011cited by this paper
• CYP2C9-CYP3A4 Protein-Protein Interactions: Role of the Hydrophobic N Terminus

  2010cited by this paper
• Cytochrome P450 3A4 mRNA Is a More Reliable Marker than CYP3A4 Activity for Detecting Pregnane X Receptor-Activated Induction of Drug-Metabolizing Enzymes

  2010cited by this paper
• Camptothecin Attenuates Cytochrome P450 3A4 Induction by Blocking the Activation of Human Pregnane X Receptor

  2010cited by this paper
• Therapeutic Protein–Drug Interactions and Implications for Drug Development

  2010cited by this paper
• CYP-Mediated Therapeutic Protein-Drug Interactions

  2010cited by this paper
• Induction of CYP2B6 and CYP3A4 expression by 1-aminobenzotriazole (ABT) in human hepatocytes.

  2010cited by this paper
• In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates

  2009cited by this paper
• Di(2-ethylhexyl) phthalate Is a Highly Potent Agonist for the Human Constitutive Androstane Receptor Splice Variant CAR2

  2009cited by this paper
• Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines

  2009cited by this paper
• Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells

  2009cited by this paper
• In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective

  2009cited by this paper
• Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes

  2009cited by this paper
• Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction

  2008cited by this paper
• PREDICTION OF DRUG-DRUG INTERACTIONS FROM IN VITRO INDUCTION DATA

  2008cited by this paper
• A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor

  2008cited by this paper
• Microscale culture of human liver cells for drug development

  2008cited by this paper
• Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

  2008cited by this paper
• Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro–in vivo correlations

  2007cited by this paper
• The Dietary Isothiocyanate Sulforaphane Is an Antagonist of the Human Steroid and Xenobiotic Nuclear Receptor

  2007cited by this paper
• Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?

  2007cited by this paper
• Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies

  2007cited by this paper
• Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs

  2007cited by this paper
• Comparison of midazolam and simvastatin as cytochrome P450 3A probes

  2006cited by this paper
• Regulation of drug-metabolizing enzymes and transporters in inflammation.

  2006cited by this paper
• CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications

  2006cited by this paper
• Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions.

  2006cited by this paper
• Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.

  2005cited by this paper
• Role of microtubules network in CYP genes expression.

  2005cited by this paper
• Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways

  2005cited by this paper
• Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

  2005cited by this paper
• Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity

  2004cited by this paper
• Transcriptional suppression of cytochrome P450 genes by endogenous and exogenous chemicals.

  2004cited by this paper
• A Structural Basis for Constitutive Activity in the Human CAR/RXRα Heterodimer

  2004cited by this paper
• Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid

  2004cited by this paper
• A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer.

  2004cited by this paper
• Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide

  2004cited by this paper
• Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation.

  2003cited by this paper
• Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.

  2003cited by this paper
• Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors.

  2003cited by this paper
• The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective

  2003cited by this paper
• Identification of a Novel Human Constitutive Androstane Receptor (CAR) Agonist and Its Use in the Identification of CAR Target Genes*

  2003cited by this paper
• Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells

  2002cited by this paper
• Use of long-term cultures of human hepatocytes to study cytochrome P450 gene expression.

  2002cited by this paper
• Putative Role of the Orphan Nuclear Receptor SXR (Steroid and Xenobiotic Receptor) in the Mechanism of CYP3A4 Inhibition by Xenobiotics*

  2002cited by this paper
• Expression and Induction of CYP2C P450 Enzymes in Primary Cultures of Human Hepatocytes

  2002cited by this paper
• Assembly-dependent trafficking assays in the detection of receptor-receptor interactions.

  2002cited by this paper
• Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.

  2002cited by this paper
• The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

  2001cited by this paper
• Induction of CYP2C genes in human hepatocytes in primary culture.

  2001cited by this paper
• Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects

  2001cited by this paper
• Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions

  2001cited by this paper
• Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor.

  2001cited by this paper
• Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

  2000cited by this paper
• Regulation of cytochrome P450 (CYP) genes by nuclear receptors.

  2000cited by this paper
• Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.

  2000cited by this paper
• Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes

  2000cited by this paper
• Effect of the Endothelin‐Receptor Antagonist Bosentan on the Pharmacokinetics and Pharmacodynamics of Warfarin

  1999cited by this paper
• Phenobarbital-Responsive Nuclear Translocation of the Receptor CAR in Induction of the CYP2B Gene

  1999cited by this paper
• Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin.

  1997cited by this paper
• Activation of carcinogens by human liver cytochromes P-450.

  1990cited by this paper
• The mechanism of the warfarin‐rifampin drug interaction in humans

  1987cited by this paper

• Microfabricated Liver-on-a-Chip with Membrane-Free Endothelial-Hepatic Interface for Long-Term Culture and Drug-Induced Liver Injury Modeling.

  2026cites this paper
• Combining the novel all-human co-cultured hepatocytes system with physiologically based pharmacokinetic modeling to assess the translatability of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase induction data.

  2026cites this paper
• Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidance.

  2025cites this paper
• Quantitative clinical risk assessment of CYP2C, UDP-glucuronosyltransferase, P-glycoprotein induction, and complex drug-drug interactions using TruVivo human hepatocyte triculture platform.

  2025cites this paper
• Evaluation of a human 3D multicellular hepatic spheroid model as a platform for studying hepatic transporters

  2025cites this paper
• Predicting Systemic and Liver Bosentan Exposure Using Physiologically‐Based Pharmacokinetic Modeling

  2025cites this paper
• Influence of 3-dimensional architecture and coculture on in vitro CYP enzyme metabolism and induction: Benchmarking human hepatic spheroids for studies in drug development.

  2025cites this paper
• Cannabidiol and Δ9-tetrahydrocannabinol induce drug-metabolizing enzymes, but not transporters, in human hepatocytes: Implications for predicting complex cannabinoid-drug interactions.

  2025cites this paper
• Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes

  2024influential citation
• Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective

  2024cites this paper
• Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic

  2024influential citation
• Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin

  2023cites this paper
• Combined Oral Contraceptives As Victims of Drug Interactions

  2023cites this paper
• Evaluating Drug–Drug Interaction Risk Associated with Peptide Analogs Using advanced In Vitro Systems

  2023influential citation
• Dicloxacillin‐warfarin drug–drug interaction—A register‐based study and in vitro investigations in 3D spheroid primary human hepatocytes

  2023cites this paper
• Isotretinoin and its Metabolites Alter mRNA of Multiple Enzyme and Transporter Genes In Vitro, but Downregulation of Organic Anion Transporting Polypeptide Does Not Translate to the Clinic

  2022cites this paper
• Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response

  2022cites this paper
• A rodent thyroid-liver chip to capture thyroid toxicity on organ functional level.

  2022cites this paper
• 3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction

  2022cites this paper
• In Vitro CYP450 Enzyme Downregulation by GLP-1/Glucagon Coagonist Does Not Translate to Observed Drug-Drug Interactions in the Clinic

  2022cites this paper
• In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

  2021cites this paper
• Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates.

  2021cites this paper
• Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective

  2021cites this paper
• PBPK modeling to predict drug‐drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction

  2021cites this paper
• Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer

  2020cites this paper
• A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates.

  2020cites this paper
• Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes

  2020influential citation
• Enrichment-free High-throughput Liquid Chromatography–Multiple-Reaction Monitoring Quantification of Cytochrome P450 Proteins in Plated Human Hepatocytes Direct from 96-Well Plates Enables Routine Protein Induction Measurements

  2020cites this paper
• Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab

  2020cites this paper
• Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib

  2020cites this paper
• REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

  2019cites this paper
• Risk of CYP2C9 induction analyzed by a relative factor approach with human hepatocytes.

  2019cites this paper
• Utility of In Vitro Bioactivity as a Lower Bound Estimate of In Vivo Adverse Effect Levels and in Risk-Based Prioritization.

  2019cites this paper
• CYP1A2 down-regulation by obeticholic acid: usefulness as a positive control for the in vitro evaluation of drug-drug interactions.

  2019cites this paper
• Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib

  2019cites this paper
• [In silico prediction models of the induction of drug-metabolizing enzymes for drug discovery].

  2019cites this paper
• Does In Vitro Cytochrome P450 Downregulation Translate to In Vivo Drug‐Drug Interactions? Preclinical and Clinical Studies With 13‐cis‐Retinoic Acid

  2019cites this paper
• In Vitro and In Vivo Methods to Assess Pharmacokinetic Drug-Drug Interactions in Drug Discovery and Development.

  2019cites this paper
• Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates

  2019cites this paper
• Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes

  2018influential citation
• CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption

  2018cites this paper
• Considerations from the Innovation and Quality Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA In Vitro Response Thresholds, Variability, and Clinical Relevance

  2018cites this paper
• In Vitro to In Vivo Translation of Complex Drug-Drug Interactions Involving Retinoic Acid

  2018influential citation
• Characterization of CYP2C Induction in Cryopreserved Human Hepatocytes and Its Application in the Prediction of the Clinical Consequences of the Induction.

  2018cites this paper
• 50th Anniversary Celebration Collection — Minireview Combined Oral Contraceptives As Victims of Drug Interactions S

  year unknowninfluential citation